A recent study by Emory University researchers provides new insights into why the mRNA vaccines developed to fight COVID-19 in 2021 are less effective in patients with autoimmune diseases.
Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...